Pharmacological Targeting of RAD6 Enzyme-mediated Translesion Synthesis Overcomes Resistance to Platinum-based Drugs

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2017 May 12

PMID 28490629

Citations 22

Authors

Matthew A Sanders

Brittany Haynes

Pratima Nangia-Makker

Lisa A Polin

Malathy P Shekhar

Affiliations

Soon will be listed here.

Abstract

Platinum drug-induced cross-link repair requires the concerted activities of translesion synthesis (TLS), Fanconi anemia (FA), and homologous recombination repair pathways. The E2 ubiquitin-conjugating enzyme RAD6 is essential for TLS. Here, we show that RAD6 plays a universal role in platinum-based drug tolerance. Using a novel RAD6-selective small-molecule inhibitor (SMI#9) targeting the RAD6 catalytic site, we demonstrate that SMI#9 potentiates the sensitivities of cancer cells with innate or acquired cisplatin or oxaliplatin resistance. 5-Iododeoxyuridine/5-chlorodeoxyuridine pulse-labeling experiments showed that RAD6 is necessary for overcoming cisplatin-induced replication fork stalling, as replication-restart was impaired in both SMI#9-pretreated and -silenced cells. Consistent with the role of RAD6/TLS in late-S phase, SMI#9-induced DNA replication inhibition occurred preferentially in mid/late-S phase. The compromised DNA repair and chemosensitization induced by SMI#9 or depletion were associated with decreased platinum drug-induced proliferating cell nuclear antigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, respectively) and with attenuated FANCD2, RAD6, γH2AX, and POL η foci formation and cisplatin-adduct removal. SMI#9 pretreatment synergistically increased cisplatin inhibition of MDA-MB-231 triple-negative breast cancer cell proliferation and tumor growth. Using an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that γH2AX and monoubiquitinated PCNA and FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that γH2AX, PCNA, and FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells. SMI#9 pretreatment sensitized HCT116-OxR cells to oxaliplatin. These data deepen insights into the vital role of RAD6/TLS in platinum drug tolerance and reveal clinical benefits of targeting RAD6 with SMI#9 for managing chemoresistant cancers.

Citing Articles

Synthesis and Biological Evaluation of Novel Triazine Analogs as Rad6 Inhibitors.

Lin Q, Gajan A, Nguyen I, Sharma S, Nangia-Makker P, Firestine S Pharm Res. 2025; .

PMID: 40021546 DOI: 10.1007/s11095-025-03838-y.

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.

Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y Mol Cancer. 2024; 23(1):148.

PMID: 39048965 PMC: 11270804. DOI: 10.1186/s12943-024-02046-3.

The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer.

Rong Z, Zheng K, Chen J, Jin X J Cancer Res Clin Oncol. 2024; 150(3):154.

PMID: 38521878 PMC: 10960765. DOI: 10.1007/s00432-024-05659-9.

RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.

Haynes B, Cunningham K, Shekhar M BMC Cancer. 2022; 22(1):1073.

PMID: 36258187 PMC: 9578210. DOI: 10.1186/s12885-022-10119-z.

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

Spanjaard A, Shah R, de Groot D, Buoninfante O, Morris B, Lieftink C Nucleic Acids Res. 2022; 50(13):7420-7435.

PMID: 35819193 PMC: 9303390. DOI: 10.1093/nar/gkac545.

References

Liu M, Mo Q, Wei C, Qin Q, Huang Z, He J . Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett. 2013; 5(3):983-991. PMC: 3576281. DOI: 10.3892/ol.2012.1093. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Koken M, Smit E, Oostra B, Hagemeijer A, BOOTSMA D, Hoeijmakers J . Localization of two human homologs, HHR6A and HHR6B, of the yeast DNA repair gene RAD6 to chromosomes Xq24-q25 and 5q23-q31. Genomics. 1992; 12(3):447-53. DOI: 10.1016/0888-7543(92)90433-s. View

Geng L, Huntoon C, Karnitz L . RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. J Cell Biol. 2010; 191(2):249-57. PMC: 2958487. DOI: 10.1083/jcb.201005101. View

Salehan M, Morse H . DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci. 2013; 70(1):31-40. DOI: 10.1080/09674845.2013.11669927. View

Parker J, Ulrich H . Mechanistic analysis of PCNA poly-ubiquitylation by the ubiquitin protein ligases Rad18 and Rad5. EMBO J. 2009; 28(23):3657-66. PMC: 2770100. DOI: 10.1038/emboj.2009.303. View

Williams S, Longerich S, Sung P, Vaziri C, Kupfer G . The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI. Blood. 2011; 117(19):5078-87. PMC: 3109534. DOI: 10.1182/blood-2010-10-311761. View

Kannouche P, Wing J, Lehmann A . Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. Mol Cell. 2004; 14(4):491-500. DOI: 10.1016/s1097-2765(04)00259-x. View

Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick S . Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst). 2010; 9(7):745-53. PMC: 4331052. DOI: 10.1016/j.dnarep.2010.03.010. View

10.

Lehmann A, Niimi A, Ogi T, Brown S, Sabbioneda S, Wing J . Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair (Amst). 2007; 6(7):891-9. DOI: 10.1016/j.dnarep.2007.02.003. View

11.

Yokochi T, Gilbert D . Replication labeling with halogenated thymidine analogs. Curr Protoc Cell Biol. 2008; Chapter 22:Unit 22.10. DOI: 10.1002/0471143030.cb2210s35. View

12.

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma R . DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8(3):193-204. DOI: 10.1038/nrc2342. View

13.

Haynes B, Saadat N, Myung B, Shekhar M . Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev Mutat Res. 2015; 763:258-66. PMC: 4369322. DOI: 10.1016/j.mrrev.2014.11.005. View

14.

Jazaeri A, Shibata E, Park J, Bryant J, Conaway M, Modesitt S . Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther. 2013; 12(10):1958-67. PMC: 3795967. DOI: 10.1158/1535-7163.MCT-12-1028. View

15.

Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho T, Scharer O . The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009; 326(5960):1698-701. PMC: 2909596. DOI: 10.1126/science.1182372. View

16.

Kannouche P, Lehmann A . Ubiquitination of PCNA and the polymerase switch in human cells. Cell Cycle. 2004; 3(8):1011-3. View

17.

Moldovan G, DAndrea A . How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009; 43:223-49. PMC: 2830711. DOI: 10.1146/annurev-genet-102108-134222. View

18.

Thompson L, Hinz J . Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res. 2009; 668(1-2):54-72. PMC: 2714807. DOI: 10.1016/j.mrfmmm.2009.02.003. View

19.

Lawrence C . The RAD6 DNA repair pathway in Saccharomyces cerevisiae: what does it do, and how does it do it?. Bioessays. 1994; 16(4):253-8. DOI: 10.1002/bies.950160408. View

20.

Diamant N, Hendel A, Vered I, Carell T, Reissner T, de Wind N . DNA damage bypass operates in the S and G2 phases of the cell cycle and exhibits differential mutagenicity. Nucleic Acids Res. 2011; 40(1):170-80. PMC: 3245908. DOI: 10.1093/nar/gkr596. View